Erythrocyte Complement Receptor 1 and Alzheimer Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CHU de Reims
ClinicalTrials.gov Identifier:
NCT01565434
First received: March 26, 2012
Last updated: June 8, 2016
Last verified: March 2012

March 26, 2012
June 8, 2016
February 2012
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01565434 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Erythrocyte Complement Receptor 1 and Alzheimer Disease
Not Provided
Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.
Not Provided
Interventional
Not Provided
Primary Purpose: Screening
Alzheimer Disease
Other: CR1 impact
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
April 2015
Not Provided

Inclusion Criteria:

  • caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects

Exclusion Criteria:

  • diseases modifying CR1 physiology
Both
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01565434
PA11014
No
Not Provided
Not Provided
CHU de Reims
CHU de Reims
Not Provided
Not Provided
CHU de Reims
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP